trial

Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

NCTId NCT00821444
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 11 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2009-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
11 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2009-01
Primary completion
2009-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ZiprasidoneB16 FastedB16 Fed

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE1
Primary Completion Date
2009-03
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
B16 Fasted
drug
B16 Fed
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Healthy
indication
Schizophrenia
indication